دورية أكاديمية
Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus.
| العنوان: | Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus. |
|---|---|
| المؤلفون: | Wang L; Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China., Peng J; Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China., Chen J; Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Aug 05; Vol. 15, pp. 1409556. Date of Electronic Publication: 2024 Aug 05 (Print Publication: 2024). |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Antibodies, Monoclonal, Humanized*/therapeutic use , Linear IgA Bullous Dermatosis*/drug therapy , Linear IgA Bullous Dermatosis*/diagnosis , Pruritus*/drug therapy , Pruritus*/etiology , Pruritus*/immunology, Humans ; Male ; Treatment Outcome ; Female ; Adult ; Middle Aged ; Skin/pathology |
| مستخلص: | Linear IgA bullous dermatosis (LABD) is an acquired autoimmune subepidermal blistering disorder. Diagnosis always relies on skin pathology and direct immunofluorescence (DIF), with typical linear deposits of IgA along the basement membrane zone (BMZ). The typical clinical manifestation is tense bullae arranged like the "string of pearls" companied with severe pruritus. Dapsone is often considered first-line therapy for LABD, and it is necessary to test the HLA-B*1301 gene to prevent the occurrence of dapsone-induced hypersensitivity syndrome (DHS). Here we report a case of LABD resistant to corticosteroid and sulfasalazine, while waiting for HLA-B*1301 gene test results, dupilumab was used to control severe pruritus. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Wang, Peng and Chen.) |
| References: | JAAD Case Rep. 2023 Dec 07;44:44-46. (PMID: 38292583) J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. (PMID: 29471919) JAMA Dermatol. 2018 Apr 1;154(4):441-446. (PMID: 29541744) Cureus. 2023 Mar 21;15(3):e36481. (PMID: 37090290) Clin Dermatol. 2012 Jan-Feb;30(1):38-50. (PMID: 22137225) J Invest Dermatol. 1996 Apr;106(4):734-8. (PMID: 8618013) J Invest Dermatol. 2013 Nov;133(11):2642-2644. (PMID: 23604100) J Am Acad Dermatol. 2020 Jul;83(1):46-52. (PMID: 32179082) JAAD Case Rep. 2023 Jun 10;38:79-81. (PMID: 37600741) JAMA Dermatol. 2023 Sep 1;159(9):953-960. (PMID: 37531116) J Invest Dermatol. 1999 Dec;113(6):947-53. (PMID: 10594735) JAMA Dermatol. 2021 Feb 1;157(2):221. (PMID: 33325993) Clin Dermatol. 2001 Nov-Dec;19(6):719-27. (PMID: 11705681) |
| فهرسة مساهمة: | Keywords: HLA-B*1301; dapsone; dupilumab; linear IgA bullous dermatosis (LABD); pruritus |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 420K487FSG (dupilumab) |
| تواريخ الأحداث: | Date Created: 20240820 Date Completed: 20240820 Latest Revision: 20240821 |
| رمز التحديث: | 20240821 |
| مُعرف محوري في PubMed: | PMC11330783 |
| DOI: | 10.3389/fimmu.2024.1409556 |
| PMID: | 39161758 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1409556 |